PML targeting eradicates quiescent leukaemia-initiating cells

Keisuke Ito, Rosa Bernardi, Alessandro Morotti, Sahoko Matsuoka, Giuseppe Saglio, Yasuo Ikeda, Jacalyn Rosenblatt, David E. Avigan, Julie Teruya-Feldstein, Pier Paolo Pandolfi

Research output: Contribution to journalArticle

422 Citations (Scopus)

Abstract

The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.

Original languageEnglish (US)
Pages (from-to)1072-1078
Number of pages7
JournalNature
Volume453
Issue number7198
DOIs
StatePublished - Jun 19 2008
Externally publishedYes

Fingerprint

Protein Transport
Leukemia
Hematopoietic Stem Cells
Neoplasms
Maintenance
Recurrence
Neoplastic Stem Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Pharmacology
Drug Therapy
Promyelocytic Leukemia Protein
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • General

Cite this

Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., ... Pandolfi, P. P. (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 453(7198), 1072-1078. https://doi.org/10.1038/nature07016

PML targeting eradicates quiescent leukaemia-initiating cells. / Ito, Keisuke; Bernardi, Rosa; Morotti, Alessandro; Matsuoka, Sahoko; Saglio, Giuseppe; Ikeda, Yasuo; Rosenblatt, Jacalyn; Avigan, David E.; Teruya-Feldstein, Julie; Pandolfi, Pier Paolo.

In: Nature, Vol. 453, No. 7198, 19.06.2008, p. 1072-1078.

Research output: Contribution to journalArticle

Ito, K, Bernardi, R, Morotti, A, Matsuoka, S, Saglio, G, Ikeda, Y, Rosenblatt, J, Avigan, DE, Teruya-Feldstein, J & Pandolfi, PP 2008, 'PML targeting eradicates quiescent leukaemia-initiating cells', Nature, vol. 453, no. 7198, pp. 1072-1078. https://doi.org/10.1038/nature07016
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008 Jun 19;453(7198):1072-1078. https://doi.org/10.1038/nature07016
Ito, Keisuke ; Bernardi, Rosa ; Morotti, Alessandro ; Matsuoka, Sahoko ; Saglio, Giuseppe ; Ikeda, Yasuo ; Rosenblatt, Jacalyn ; Avigan, David E. ; Teruya-Feldstein, Julie ; Pandolfi, Pier Paolo. / PML targeting eradicates quiescent leukaemia-initiating cells. In: Nature. 2008 ; Vol. 453, No. 7198. pp. 1072-1078.
@article{74a4405aee3a480ab05f4fa5282e595d,
title = "PML targeting eradicates quiescent leukaemia-initiating cells",
abstract = "The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.",
author = "Keisuke Ito and Rosa Bernardi and Alessandro Morotti and Sahoko Matsuoka and Giuseppe Saglio and Yasuo Ikeda and Jacalyn Rosenblatt and Avigan, {David E.} and Julie Teruya-Feldstein and Pandolfi, {Pier Paolo}",
year = "2008",
month = "6",
day = "19",
doi = "10.1038/nature07016",
language = "English (US)",
volume = "453",
pages = "1072--1078",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7198",

}

TY - JOUR

T1 - PML targeting eradicates quiescent leukaemia-initiating cells

AU - Ito, Keisuke

AU - Bernardi, Rosa

AU - Morotti, Alessandro

AU - Matsuoka, Sahoko

AU - Saglio, Giuseppe

AU - Ikeda, Yasuo

AU - Rosenblatt, Jacalyn

AU - Avigan, David E.

AU - Teruya-Feldstein, Julie

AU - Pandolfi, Pier Paolo

PY - 2008/6/19

Y1 - 2008/6/19

N2 - The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.

AB - The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.

UR - http://www.scopus.com/inward/record.url?scp=44349166602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349166602&partnerID=8YFLogxK

U2 - 10.1038/nature07016

DO - 10.1038/nature07016

M3 - Article

C2 - 18469801

AN - SCOPUS:44349166602

VL - 453

SP - 1072

EP - 1078

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7198

ER -